Sexual health is defined by the World Health Organization as the integration of somatic, emotional, intellectual, and social aspects in ways that are positively enriching and that will enhance personality, communication, and love. The female sexual response is multifaceted and involves neurovascular, endocrine, and psychosocial factors. Optimal female sexual health comprises physical, mental, and emotional aspects, and these are the context in which a woman experiences desire, arousal, and orgasm. Sexual dysfunction in females is a complex and highly prevalent disease, and is commonly associated with the quality of life. Several factors influence female sexual function, including physiological and psychosocial factors. This article discusses models of female sexual response, defines and categorizes female sexual dysfunction, and identifies therapeutic modalities for female patients with sexual dysfunction.
Introduction
Sexual health is defined by the World Health Organization as the integration of somatic, emotional, intellectual, and social aspects in ways that are positively enriching and that will enhance personality, communication, and love. The female sexual response is complex and is influenced by a multitude of factors including a complex interplay of physiological, psychological, and interpersonal components. Despite improved knowledge of the female pelvic anatomy and recent understanding of the neurobiology and pharmacology of sexual responses, specifying a normal sexual response in women remains highly challenging and controversial. Traditionally, the female sexual response cycle was based on a linear model proposed by Masters and Johnson in the 1960s. 1 This model proposed a succession through four phases of excitement, plateau, orgasm, and resolution, each of which has associated genital and extragenital responses. Despite the tremendous influence of the Masters and Johnson model, there are several limitations and criticisms.
2 First, the model fails to explain the highly variable patterns of response seen from one woman to another or even the variability in response from one episode to another in the same woman. Second, the model predominantly focuses only on the physiological aspects of the sexual response and does not reflect the importance of subjective, psychological, or interpersonal aspects of the sexual response. Finally, no indication is given of the importance of sexual desire or libido in their model.
To overcome these deficiencies, a three-phase model of the sexual response was proposed by Helen Singer Kaplan. 3 According to this model, the sexual response cycle is conceptualized as including three essential phases: desire, excitement, and orgasm. The first phase of sexual desire of Kaplan's model consists of physiological and psychological components of sexual desire or libido, which are mediated by brain centers in the limbic system but are also affected to a degree by hormonal (i.e., androgenic) and psychosocial factors. The desire phase is thought to be a necessary precursor to the development of excitement and subsequent orgasm in men and women. Kaplan's three-stage model was used as the basis of the Diagnostic and Statistical Manual of Mental Disorders, 4 th edition, classification of female sexual dysfunction. 4 More recently, in an attempt to reflect women's true experiences of sexual responses, Basson proposed a circular model that incorporates psychological and social aspects into female sexual function, such as emotional intimacy and emotional satisfaction as well as sexual desire and physical satisfaction. 5 The model incorporates biological, psychological, and other factors in a morecomprehensive framework. An important new concept in Basson's model is that feelings of subjective arousal or emotional involvement do not always correlate with physiological measures of genital congestion. It is also possible for a woman to experience healthy sexual vasocongestion or genital lubrication with minimal or no feelings of sexual arousal or excitement. Other differences in Basson's model from the traditional model of female sexual response are a discounting of the previously held notion regarding the primacy of spontaneous sexual desire in women and that orgasm and resolution are not essential in the sexual response cycle. These features set the current model apart from previous models of sexual response and may make it more reflective of women's actual day-to-day sexual experiences. However, there are important limitations to this model that need to be recognized. First, it is largely based on clinical observations and lacks experimental verification. Moreover, the model is largely intimacy-based and may exclude some women whose sexual desires and arousal are not linked to intimacy. Nevertheless, by shifting the focus to include subjective and interpersonal factors and by recognizing the nonlinear nature of women's sexual experiences, Basson's model greatly contributes to the current understanding of a healthy sexual response in women. 6 
Epidemiology of Female Sexual Dysfunction
In the most widely cited study based on the US National Health and Social Life Survey of 1992, which evaluated a sample of 1749 women aged 18-59 years, 43% reported sexual dysfunction. Low libido was the most common complaint (51%) followed by problems with arousal (33%) and pain disorders (16%). 7 Another international survey, including 4507 women aged 18-59 years, revealed that 34% of the participants had decreased sexual interest, and 19% did not consider sexual intercourse to be pleasurable. 8 Unfortunately, these data provide no information on prevalence rates in women over the age of 59 years or whether the sexual dysfunction was problematic or a cause of distress to the affected individual. A survey from an older population of women (> 60 years) showed that two-thirds of the 448 women were sexually inactive, 12% of married women had difficulty with intercourse, and approximately 14% experienced pain with intercourse. 9 Whether a woman was sexually active was strongly correlated with her marital status. However, the study of older women lacked specific measures of female sexual dysfunction. A recent study including a female population up to age 79 years reported sexual dysfunction in approximately 35% of participants. 10 In that study, 71% of women were sexually active, and 33% of the sexually active women were classified as having female sexual dysfunction by the answer of "somewhat of a problem" or "very much a problem" in at least one of the four domains studied, including a lack of interest, lack of enjoyment, difficulty in becoming aroused, and difficulty in having an orgasm. Although female sexual dysfunction is recognized as a highly prevalent health problem, some controversy exists regarding the prevalence of female sexual dysfunction. The epidemiology of female sexual dysfunction is still not well understood. This may be the result of variations in assessment techniques or the lack of standardized definitions.
Definitions and Classification of Female Sexual Dysfunction
One of the major barriers to the advancement of research on female sexual dysfunction is the absence of a well-defined diagnostic classification system. In 1998, The Sexual Function Health Council of the American Foundation for Urologic Disease convened an interdisciplinary consensus conference panel consisting of 19 experts on female sexual dysfunction selected from five countries. The purpose was to evaluate and revise the existing classifications and definitions of female sexual dysfunction to include psychogenic and organically based disorders. 11 An important component of the diagnostic system is the personal distress criterion, meaning that a condition is considered a disorder only if it causes distress for the woman experiencing the condition. The system uses the four major categories as described in the Diagnostic and Statistical Manual of Mental Disorders, 4 th edition, and the International Classification of Diseases, 10 th Revision, but the definitions of several disorders were changed to reflect current clinical and research practice and a new category of sexual pain disorder was added (Table 1) . This system was subsequently revised and further expanded, and is now widely accepted by healthcare providers and provides guidelines for diagnosis and treatment. [12] [13] [14] The classifications can be subtyped as lifelong versus acquired, generalized versus situational, and organic versus psychological or mixed.
Sexual Desire Disorders

Hypoactive sexual desire disorder (HSDD)
HSDD is a spectrum of diseases that causes personal distress owing to a persistent or recurring deficiency (or absence) of sexual fantasies and thoughts and a lack of receptivity to sexual activity.
11-14 HSDD may result from psychological/emotional factors or be secondary to physiologic problems. Natural menopause, surgically or medically induced menopause, depression and its treatments, and endocrine disorders are the most common causes that disrupt the normal female hormonal milieu, resulting in inhibited sexual desire. 15, 16 Long-term conflicting relationships have also been shown to adversely affect sexual desire. 
Sexual aversion disorder
Sexual aversion disorder is a persistent or recurrent phobic aversion leading to avoidance of sexual contact which causes personal distress. [11] [12] [13] [14] It is generally a psychologically or emotionally based problem. It is often secondary to a history of physical or sexual abuse and childhood trauma.
Sexual arousal disorder
Sexual arousal disorder is a persistent or recurring inability to attain or maintain adequate sexual excitement causing personal distress. [11] [12] [13] [14] It may be experienced as a lack of subjective excitement, somatic responses, or genital lubrication/swelling. Sexual arousal disorder may be further subclassified as subjective, genital, or combined. Subjective arousal disorder is characterized by absent or reduced feelings of sexual arousal, despite the occurrence of vaginal lubrication and genital swelling.
Genital arousal disorder is characterized by a lack of vaginal lubrication or genital swelling, despite feelings of subjective arousal. Combined sexual arousal disorder is characterized by the absence of subjective arousal and genital arousal. Decreased labial and clitoral sensations and engorgement and lack of vaginal smooth muscle relaxation can also cause sexual arousal disorder. These conditions may occur secondary to a medical/physiological basis such as diminished vaginal/clitoral blood flow, prior pelvic trauma, pelvic surgery, or medications. Psychological factors are among the other important causes of sexual arousal disorder. 
Orgasmic disorders
Orgasmic disorders are the persistent or recurrent difficulty in, delay in, or absence of attaining orgasm after sufficient sexual stimulation and arousal, which causes personal distress. [11] [12] [13] [14] Orgasmic disorders can be primary (a woman has never achieved orgasm) or secondary. Anorgasmia was observed in 24-37% of women presenting to sex therapy clinics for various reasons. 19 Primary orgasmic disorder is usually due to emotional trauma or sexual abuse. Hormonal deficiency, surgical trauma, or medications are common causes for secondary orgasmic disorder. Anorgasmia is also a common complaint in women taking selective serotonin reuptake inhibitors. 20 
Sexual Pain Disorders
Dyspareunia
Dyspareunia is recurrent or persistent genital pain associated with sexual intercourse. [11] [12] [13] [14] Dyspareunia can develop secondary to physiological or psychological disorders such as vaginal atrophy, postmenopausal decreased vaginal lubrication, damage to the pelvic nerves as a complication of pelvic surgery, fear, anxiety, or interpersonal conflict.
21-23
Vaginismus
Vaginismus is recurrent or persistent involuntary spasms of the musculature of the outer third of the vagina that interferes with vaginal penetration and causes personal distress. [11] [12] [13] [14] Vaginismus usually develops as a conditioned response to painful penetration, or secondary to psychological/emotional factors. 24 
Other sexual pain disorders
Other sexual pain disorders include recurrent persistent genital pain induced by noncoital sexual stimulation. [11] [12] [13] [14] This may include inflammatory or anatomic conditions, such as infections (i.e., herpes simplex virus), vestibulitis, prior genital mutilation or trauma, or endometriosis. 
Assessment of Female Sexual Dysfunction
It is recommended that the evaluation of female sexual dysfunction involve an interview of the couple and each partner separately. The evaluation should include a detailed medical and sexual history, with particular attention to potential psychiatric comorbidities, such as depression or anxiety, and a physical examination, including a gynecologic examination. Furthermore, a validated selfassessment questionnaire is practical, efficient, objective, and inexpensive, providing a very useful tool for research and clinical practice. In addition, the history should focus on the duration of the disorder (primary or secondary) and the psychosocial factors involved, such as any recent life changes or stressors. There are several validated self-assessment questionnaires available to evaluate female sexual function (Table 2) , [25] [26] [27] [28] [29] such as the Female Sexual Function Index (FSFI, available at www. fsfi-questionnaire.com). 27 The FSFI, which has been translated into Chinese, is a 19-item questionnaire that characterizes six domains of sexual function. More specifically, Q1 and Q2 are grouped into the desire domain, Q3-Q6 are grouped into the arousal domain, Q7-Q10 are grouped into the lubrication domain, Q11-Q13 are grouped into the orgasm domain, Q14-Q16 are grouped into the satisfaction domain, and Q17-Q19 are grouped into the pain domain ( Table 3 ). The full FSFI scores range from 2-36. A woman with a total FSFI score of ≤ 26 is considered to be at risk of sexual dysfunction. These questionnaires can also be used to monitor response to treatment.
Routine laboratory testing is not recommended unless a hormonal deficiency is suspected. Dehydroepiandrosterone sulfate reflects adrenal androgen secretion and may highlight an adrenal insufficiency. 30 Thyroidstimulating hormone may identify a thyroid dysfunction. Measurement of sex steroid levels, such as estrogen and testosterone, is seldom useful. [31] [32] [33] Specialized diagnostic tools such as duplex Doppler ultrasonography, vaginal pH measurements, and vaginal/clitoral sensory perception thresholds are not widely available and require expensive equipment. 34 Although useful for study purposes, this equipment is not essential to evaluate and diagnose patients with sexual dysfunction.
Management of Female Sexual Dysfunction
The female sexual response is multifaceted and involves neurovascular, endocrine, and psychosocial factors. Optimal female sexual health comprises physical, mental, and emotional aspects, and these are the context in which a woman experiences desire, arousal, and orgasm. Table 4 shows treatments for female sexual dysfunction. A psychosocial intervention may be necessary based on the woman's relationships, current life stressors, and sexual problems. An open discussion should take place with the patient and her partner. It is important to educate the patient and partner about the diagnosis and physiological basis of female sexual dysfunction, and to establish goals and expectations of treatment. Patients should be educated that not having orgasms with each sexual encounter does not mean that the experience was a failure, and clitoral stimulation may be more likely to lead to orgasm than coital intercourse. 35 Modifications of lifestyle, such as changing to a healthy diet, reducing stress factors, participating in regular physical activities, eliminating risk factors (smoking, drinking, illicit drug use, and obesity), and optimally treating medical diseases that can affect female sexual dysfunction such as hypertension, hyperlipidemia, and diabetes are also part of the (1) sexual-esteem questionnaire (2) sexual-preoccupation (3) internal-sexual-control (4) sexual-consciousness (5) sexual-motivation (6) sexual-anxiety (7) sexual-assertiveness (8) sexual-depression (9) external-sexual-control (10) sexual-monitoring (11) fear-of-sex (12) sexual-satisfaction management. 30, 36 The woman and her partner need to improve communication and reduce strains on the relationship when present because a strong impetus for female sexuality is intimacy. 30 The study of female sexual dysfunction has lagged behind research into male sexual health, resulting in very slow progress in developing pharmacological therapies for female sexual dysfunction. Hormonal treatment, primarily with estrogen and testosterone, is one of the mainstays of treatment for some types of female sexual dysfunction. Estrogen is important in maintaining adequate lubrication and preventing atrophy of vaginal and vulvar tissues, with many complaints of dyspareunia in menopause correlated to the decreased estrogen levels. However, studies have documented that systemic estrogen alone is insufficient to cure symptoms of sexual dysfunction. 37, 38 Additionally, estrogen treatment increases sex hormone-binding globulin levels and depletes levels of bioavailable testosterone, potentially exacerbating androgen insufficiency. Therefore, estrogen therapy, often applied topically, is commonly used for dyspareunia. 39 A review of earlier studies on the use of testosterone in postmenopausal women for low libido concluded that there are benefits in terms of improved sexual function with the addition of testosterone to standard postmenopausal hormone therapy. 40 Subsequent large, randomized control trials in both surgically menopausal [41] [42] [43] and naturally menopausal women 44 demonstrated that treatment with the addition of testosterone resulted in significant improvements in desire, arousal, responsiveness, orgasm, pleasure, and satisfaction when compared with a placebo. However, the role of androgens in treating female sexual dysfunction is still controversial because there is no information on long-term testosterone use and no established normal levels for testosterone or free testosterone in women. Furthermore, few assays can provide the necessary sensitivity and specificity to recommend widespread use of lab measurements. 45 Studies of phosphodiesterase type-5 inhibitors, dopaminergic agonists, and prostaglandins have not provided evidence of a significant benefit for female sexual dysfunction. 46, 47 In summary, women with sexual dysfunction may have problems that overlap with different stages of sexual function, arousal, desire, orgasm, or pain. Manage ment of female sexual dysfunction largely depends on the etiology. A collaborative and comprehensive evaluation, patient and partner education, and behavioral modifications, followed by individualized pharmacotherapy in selected patients should be the standard management of women with sexual dysfunction. 
Conclusions
Female sexual dysfunction is a complex and highly prevalent disease that affects a large number of women. Several factors influence female sexual function, including physiological and psychosocial factors. Assessment of female sexual dysfunction should include a complete medical and psychosocial history, and a physical examination. Routine laboratory testing is not recommended unless a hormonal deficiency is suspected. Treatment should be multidisciplinary and depends on the etiology of female sexual dysfunction. Further research in this area should attempt to better understand the physiology of female sexuality and to create (pharmacological and non-pharmacological) treatment algorithms suitable for female sexual dysfunction.
